Bli medlem
Bli medlem

Du är här

2016-05-17

Novartis International AG: Novartis Foundation and partners launch innovative hypertension program in Vietnam

Novartis International AG / Novartis Foundation and partners launch innovative
hypertension program inVietnam . Processed and transmitted by NASDAQ OMX
Corporate Solutions.The issuer is solely responsible for the content of this
announcement.
* Ho Chi Minh City Communities for Healthy Hearts Program is the second
innovative healthcare model for hypertension pioneered by the Novartis
Foundation

* Screening and treatment shifts to the community via social entrepreneurs,
while digital health technology empowers patients and health workers

* Nearly one quarter of the adult population in Vietnam has hypertension, but
only 11% of these hypertensive patients have it under control

* Program partners include Ho Chi Minh City's Provincial Health Department,
PATH, the Hanoi School of Public Health and Lotus Impact

The digital press release with multimedia content can be accessed here:

Basel, May 17, 2016
-
On the occasion of World Hypertension Day 2016, the Novartis Foundation and
its partners, including the international nonprofit organization PATH, are
announcing the launch of the Ho Chi Minh City Communities for Healthy Hearts
Program, which is designed to improve health outcomes of adults with
hypertension living in low-income households in urban Vietnam.

"I'm extremely pleased we are partnering with the Novartis Foundation to
address this significant emerging healthcare challenge in Vietnam," said PATH
president and CEO Steve Davis. "We have leveraged our collective expertise in
behavior change, health system strengthening, and technology solutions to
create a truly innovative and people-centered healthcare model. We hope to
see hypertension prevention and control made easy at the community level, for
both health workers and patients."

An international nonprofit organization, PATH saves lives, improves health and
is a leader in global health innovation. PATH has a 35 year history of
partnership in Vietnam.

Carried out in four districts in Ho Chi Minh City, covering a population of
approximately two million people, Communities for Healthy Hearts will
leverage new approaches to hypertension management by introducing social
entrepreneurs to increase access points for cardiovascular health education
and screening services. Additionally, the public and private health sectors
will collaborate closely in this patient-centered approach to strengthen
treatment and referral services. Digital health technology will empower
patients in self-management and increase patient-to-provider contact.
Learnings from this program will be evaluated to inform expansion of
hypertension control efforts in Vietnam.

"We are excited to see our hypertension work extend to Vietnam through an
innovative collaborative approach," said Ann Aerts, Head of the Novartis
Foundation. "As with our Community-based Hypertension Improvement Program
(ComHIP) in Ghana, we hope to bring hypertension prevention and detection
closer to patients to improve health outcomes and blood pressure control
levels in urban settings in a way that is sustainable at scale."

World Hypertension Day brings hypertension care and management into focus;
complications from hypertension and high blood pressure account for 9.4
million deaths worldwide every year, this is equivalent to all infectious
diseases combined.[1] Nearly 25% of the adult population in Vietnam has
hypertension,[2]but less than half of them are aware of their condition. Of
those diagnosed with hypertension, only 11% have it under control.[3] In
urban areas of Vietnam the prevalence of hypertension is higher at
33%,[4]with Ho Chi Minh City being home to the largest urban population in
the country.

The Novartis Foundation is collaborating on Communities for Healthy Hearts
with the Ho Chi Minh City's Provincial Health Department, PATH, the Hanoi
School of Public Health, and Lotus Impact.

Disclaimer

This press release contains expressed or implied forward-looking statements,
including statements that can be identified by terminology such as "launch,"
"designed," "emerging," "hope," "will," "efforts," "excited," or similar
expressions. Such forward-looking statements reflect the current views of the
Group regarding future events, and involve known and unknown risks,
uncertainties and other factors that may cause actual results to be
materially different from any future results expressed or implied by such
statements. These expectations could be affected by, among other things,
risks and factors referred to in the Risk Factors section of Novartis AG's
current Form 20-F on file with the US Securities and Exchange Commission.
Novartis is providing the information in this press release as of this date
and does not undertake any obligation to update it in the future.

About the Novartis Foundation

The Novartis Foundation is a philanthropic organization pioneering innovative
healthcare models that can have a transformational impact on the health of
the poorest populations. We work hand-in-hand with our local and global
partners to catalyze scalable and sustainable healthcare models to improve
access and health outcomes, and to accelerate efforts to eliminate leprosy
and malaria by focusing on interventions that aim to interrupt transmission.
Everything we do is grounded in evidence and innovation, and our work is a
continuous cycle of evaluation, adaptation and application. In 2015, the
operational budget for the foundation was CHF 12 million and our programs
reached 4.5 million people.

For more information, please visit:
www.novartisfoundation.org
www.youtube.com/novartisfoundation

Novartis Foundation is on Twitter. Sign up to follow @NovartisFDN
athttps://twitter.com/NovartisFDN

About Novartis

Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland,
Novartis offers a diversified portfolio to best meet these needs: innovative
medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the
only global company with leading positions in these areas. In 2015, the Group
achieved net sales of USD 49.4 billion, while R&D throughout the Group
amounted to approximately USD 8.9 billion (USD 8.7 billion excluding
impairment and amortization charges). Novartis Group companies employ
approximately 118,000 full-time-equivalent associates. Novartis products are
available in more than 180 countries around the world. For more information,
please visithttp://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis
athttp://twitter.com/novartis.

For Novartis multimedia content, please
visitwww.novartis.com/news/media-library. For questions about the site or
required registration, please contact:media.relations@novartis.com

References

[1] Lim, SS, Vos, T, Flaxman, AD et al. A comparative risk assessment of
burden of disease and injury attributable to 67 risk factors and risk factor
clusters in 21 regions, 1990-2010: a systematic analysis for the Global
Burden of Disease Study 2010. Lancet. 2012; 380: 2224-2260.
[2] Son, PT, Quang N., Viet NL., Khai PG, Wall S., Weinehall L., Bonita R.,
Byass P. Prevalence, awareness, treatment and control of hypertension in
Vietnam - results from a national survey. J Hum Hypertension. 2012. 26(4):
268-80
[3] Pham, S. Hypertension in Vietnam: From community-based studies to a
national targeted programme. Epidemiology and Global Health. Department of
Public Health and Clinical Medicine. Umeå University, Sweden, and Vietnam
National Heart Institute, Bach Mai Hospital&Hanoi Medical University. Umeå,
Sweden: Umeå University; 2012.
[4] Son et al, 2012. Prevalence, awareness, treatment and control of
hypertension in Vietnam - results from a national survey. Journal of Human
Hypertension.

# # #

Novartis Media Relations

------------------------------------------------------------
| Central media line : |
|+41 61 324 2200 |
| Eric Althoff Julie Morrow |
| |
|Novartis Global Media Relations Novartis Foundation |
|+41 61 324 7999 (direct) +41 61 696 2421 (direct) |
|+41 79 593 4202 (mobile) +41 79 224 5666 (mobile) |
|eric.althoff@novartis.com julie.morrow@novartis.com |
------------------------------------------------------------
e-mail:media.relations@novartis.com

Novartis Investor Relations

----------------------------------------------------------------------------------
| Central phone: +41 61 324 7944 |
| Samir Shah +41 61 324 7944 North America: |
| Pierre-Michel Bringer +41 61 324 1065 Richard Pulik +1 212 830 2448 |
| Thomas Hungerbuehler +41 61 324 8425 Sloan Pavsner +1 212 830 2417 |
| Isabella Zinck +41 61 324 7188 |
| |
| e-mail:investor.relations@novartis.com e-mail:investor.relations@novartis.com |
----------------------------------------------------------------------------------

Media release (PDF)
http://hugin.info/134323/R/2012955/745869.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novartis International AG via Globenewswire

HUG#2012955

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.